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Abstract
Rationale Typical users of 3,4-methylenedioxymetham-
phetamine (MDMA or “ecstasy”) are polydrug users,
combining MDMA with alcohol or cannabis [most active
compound: delta-9-tetrahydrocannabinol (THC)].
Objectives The aim of the present study was to investigate
whether co-administration of alcohol or THC with MDMA
differentially affects ongoing electroencephalogram (EEG)
oscillations compared to the administration of each drug
alone.
Methods In two separate experiments, 16 volunteers received
four different drug conditions: (1) MDMA (100 mg); (2)
alcohol clamp (blood alcohol concentration=0.6‰)o rT H C
(inhalation of 4, 6 and 6 mg, interval of 1.5 h); (3) MDMA in
combination with alcohol or THC; and (4) placebo. Before
and after drug administration, electroencephalography was
recorded during an eyes closed resting state.
Results Theta and alpha power increased after alcohol
intake compared to placebo and reduced after MDMA
intake. No interaction between alcohol and MDMA was
found. Significant MDMA × THC effects for theta and
lower-1-alphapowerindicatedthatthepowerattenuationafter
the combined intake of MDMA and THC was less than the
sumofeachdrugalone.Forthelower-2-alphaband,theintake
of MDMA or THC alone did not significantly affect power,
but the intake of combined MDMA and THC significantly
decreased lower-2-alpha power.
Conclusions The present findings indicate that the com-
bined intake of MDMA and THC, but not of MDMA and
alcohol, affects ongoing EEG oscillations differently than
the sum of either one drug alone. Changes in ongoing EEG
oscillations may be related to the impaired task perfor-
mance that has often been reported after drug intake.
Keywords MDMA.Ecstasy.Alcohol.Ethanol.THC.
Cannabis.Acute effects.Healthy volunteers.Neuronal
oscillations.EEG
Introduction
Alcohol (ethanol), cannabis and ecstasy [3,4-methylene-
dioxymethamphetamine (MDMA)] are the most commonly
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Western society. Ecstasy users typically are polydrug users
in that they combine the use of ecstasy frequently with that
of alcohol or cannabis (Barrett et al. 2005; Boys et al. 2001;
Gouzoulis-Mayfrank and Daumann 2006; Parrott 2007).
MDMA is a psychostimulant that produces euphoria,
enhanced sociability and a sense of increased empathy (de
la Torre et al. 2004). Although alcohol has both arousing
and sedating effects that are dose-dependent with high
inter-individual variability, at high blood alcohol concen-
trations (BAC>0.5 g/L), alcohol generally causes sedation
(Gulick and Gould 2007). Cannabis produces relaxation,
feelings of happiness and increased sensory perception, but
it may also produce dizziness and feelings of depression
(Green et al. 2003).
In the brain, MDMA increases the levels of available
serotonin, dopamine and norepinephrine (Colado et al.
2004; Liechti and Vollenweider 2000, 2001; Mlinar and
Corradetti 2003; Pifl et al. 1995; Sprague et al. 2004).
MDMA is usually ingested orally and rapidly absorbed.
Plasma levels peak at 1–2 h after drug intake, and
maximum behavioural and subjective effects occur around
the peak plasma levels (de la Torre et al. 2004; Dumont et
al. 2009a).
Alcohol has direct and indirect effects on multiple
neurotransmitter and neuropeptide systems (Little 1999;
Vengeliene et al. 2008), such as the inhibition of glutamate
and enhancement of inhibitory GABA neurotransmission.
Oral administration of a single dose of alcohol results in a
highly variable increase of BAC with maximal plasma
concentrations occurring 30–60 min after ingestion, after
which BAC decline steadily at an average rate of roughly
0.15 gL
−1h
−1.
The major active compound of cannabis is delta-9-
tetrahydrocannabinol (THC; Ilan et al. 2005). THC is an
agonist for cannabinoid receptors (particularly CB1). After
inhalation, THC is rapidly distributed from the blood into
the brain and other lipophilic tissues, for which it has a high
affinity. Consequently, peak plasma levels are reached
within several minutes and show a rapid decline reflecting
redistribution, whereas subjective and cognitive effects of
cannabis inhalation peak around 15–60 min and last for
several hours (Dumont et al. 2010c; Strougo et al. 2008).
Whereas the central effects of a high dose of alcohol are
generally sedative, and consequently lead to non-specific
cognitive impairments, THC and MDMA affect cognition
more specifically. The cognitive effects of THC generally
include, but are not restricted to, impairment of memory
and psychomotor function and subjective relaxation and
sedation (Zuurman et al. 2009). MDMA stimulates
psychomotor speed but not accuracy and impairs memory
function (Kuypers and Ramaekers 2007; Lamers et al.
2003). Although many reports addressed the acute
cognitive effects of MDMA, a review by our group
concluded that effects reported were generally small and
inconsistent across studies (Dumont and Verkes 2006).
Since ecstasy (MDMA) is commonly used in combination
with cannabis (THC) or alcohol (ethanol), it is important to
examine the effects of the co-administration of MDMA and
ethanol or MDMA and THC on subjective feelings and
cognitive and psychomotor performance. In two separate
studies, Dumont et al. (2008, 2010c) addressed this issue.
Although co-administration of MDMAwith ethanol reversed
subjective feelings of reduced alertness caused by alcohol,
MDMAdidnotaffectethanol-induceddelaysofpsychomotor
speed(Dumont etal.2008). Combined intake of MDMA and
ethanol did not exacerbate the impairment in memory or
psychomotor performance (Dumont et al. 2008). Whereas
MDMA stimulates psychomotor speed, co-administration of
MDMA with THC could not significantly reverse the
drowsiness or the impairments of psychomotor speed
produced by THC (Dumont et al. 2010c). Similar to the
combined intake of MDMA and ethanol, co-administration
of MDMA with THC did not appear to exacerbate the
impairments of memory (Dumont et al. 2010c).
The current paper will address the effects of these drug
combinations on electroencephalogram (EEG), a parameter
of brain function. EEG can be used to get more insight into
ongoing EEG oscillations, which are a manifestation of
neuronal oscillations. EEG oscillations may be related to a
variety of factors such as levels of alertness (Oken et al.
2006) and information processing (e.g., Klimesch 1999)
and are affected by drug intake. For example, drowsiness
during an eyes closed resting condition is associated with
increased theta power and decreased alpha and beta power
(Oken et al. 2006). Furthermore, a role of EEG oscillations
in human information processing such as attention, active
inhibition, memory and integrative functions has been
demonstrated (Klimesch 1999; Knyazev 2007; Sauseng et
al. 2010). For example, a higher memory load in a working
memory task has been related to increased theta and alpha
power. Based on these and other findings, it has been
suggested that theta oscillations play a role in memory
functions and alpha oscillations in the active inhibition of
visual processing (Jensen et al. 2002; Jensen and Tesche
2002). Psychoactive substances also affect EEG oscillations
(Mitchell et al. 2008).
Onlyfewstudiesexaminedtheeffectsoftheadministration
ofMDMA,THCandethanolonelectrocorticalactivityduring
a resting state (i.e. ongoing EEG oscillations), and the effects
of the co-administration of MDMA with either THC or
ethanol have not been addressed so far. To our knowledge,
only one published study investigated the acute effects of
MDMAonEEGpower duringa restingconditioninMDMA-
naive volunteers, revealing decreased theta and alpha power
after MDMA administration (Frei et al. 2001).
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consistent finding after acute cannabis administration is
decreased theta power (Böcker et al. 2010; Ilan et al. 2004,
2005; Zuurman et al. 2008, 2010). THC effects on alpha
power are more variable, varying from increased alpha
power (but only during a state in which THC induced
feelings of euphoria; Lukas et al. 1995) or no effects on
alpha power (Böcker et al. 2010; Ilan et al. 2004, 2005;
Zuurman et al. 2008, 2010) during a resting state. The
decrease in theta power after cannabis use was dose-related
and correlated with decreased working memory performance
(Böcker et al. 2010). It has been speculated that decreased
theta power after cannabis administration reflects the
desynchronization of ongoing theta oscillations, which
interferes with phase resetting of theta that is needed for
optimal memory performance (Böcker et al. 2010). Another
explanation that has been proposed is that theta power
attenuation after cannabis intake may reflect increased
activity of the default mode network (DMN), which
interferes with information processing (Böcker et al. 2010).
The DMN is a group of brain areas that are functionally
related, active during rest and deactivated during externally
directed behaviour (Greicius et al. 2003). It is hypothesized
that activity in the DMN reflects mind wandering or
internally oriented attention. However, the relation between
theta oscillations and activity in the DMN has not been fully
established, and activity in the DMN has also been related to
alpha and beta oscillations and alpha synchronization (Jann
et al. 2009; Laufs 2008).
The effects of acute ethanol intake on EEG power have
been investigated more intensively (Little 1999). The acute
administration of ethanol consistently increases theta and
alpha power (particularly within the lower-1 alpha frequency
range,8–10 Hz; e.g. Ilanand Gevins 2001; Lukas et al. 1986;
Stenberg et al. 1994;T r a ne ta l .2004), although alpha power
returned to normal levels 60 min after ethanol administration
(Lukas et al. 1986). Increased alpha power after alcohol
consumption has been shown to correlate positively with
feelings of euphoria (Lukas et al. 1986). Furthermore, a
reductioninpeakpowerfrequencyforthetaandlower-2alpha
(Ehlers et al. 1989) has been demonstrated with alcohol
consumption.
In summary, whereas the administration of MDMA
alone or THC alone decreases theta power, intake of
ethanol alone increases theta power. Similar patterns have
been found for alpha power, which decreases after MDMA
and increases after ethanol. The question remains whether
combined intake of MDMA and THC or ethanol has an
additive effect or an interaction effect on theta and alpha
oscillations. In two separate prospective placebo-controlled
within-subject studies, we aim to assess the effects of acute
administration of MDMA on electrocortical power, alone and
in combination with ethanol (study 1) or THC (study 2).
Based on previous EEG studies, we expect that
MDMA decreases theta and alpha power, THC decreases
theta but not alpha power, and ethanol increases theta
and alpha power. The question remains whether
ethanol could counteract the MDMA effects on theta
and alpha power and whether MDMA and THC would
exacerbate the theta power attenuation after a single
drug intake.
Methods
Study design
Data were collected in two separate studies that have
already been described in detail in recently published
papers: (a) study 1: MDMA × ethanol interaction study
(Dumont et al. 2008) and (b) study 2: MDMA × THC
interaction study (Dumont et al. 2010c). Studies were
similar in design; relevant discrepancies between studies
are described in the pertaining sections and presented in
Table 1. Both studies utilized a four-way, double-blind,
randomized, crossover and placebo-controlled design.
Sixteen volunteers were randomly assigned to one of four
treatment sequences.
Study 1 Each volunteer received a capsule containing either
100 mg MDMA or placebo and a placebo-controlled intrave-
nous ethanol clamp as described below, with a washout of
7 days between treatments. So, each participant attended four
drug sessions: (1) placebo+placebo, (2) MDMA+placebo
(i.e. MDMA alone), (3) ethanol+placebo (i.e. ethanol
alone) and (4) MDMA+ethanol.
Study 2 Each volunteer received a capsule containing either
100 mg MDMA or placebo and inhaled THC or placebo
vapour as described below, with a washout of 7 days
between each treatment. So, each participant attended four
drug sessions: (1) placebo+placebo, (2) MDMA+placebo
(i.e. MDMA alone), (3) THC+placebo (i.e. THC alone)
and (4) MDMA+THC.
Participants
Study 1 Participants included 16 healthy volunteers (nine
men, seven women) who are regular users of ecstasy (at
least eight exposures in the last 2 years) and alcohol (at
least one exposure per week), 22.1±2.9 (mean ± SD)years
of age (range 18-29). Lifetime ecstasy exposure was on
average 95 (SD=138, range 14–431). More detailed
demographic data have been reported elsewhere (Dumont
et al. 2008).
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men, 4 women) who are regular users of ecstasy (at least
eight exposures in the last 2 years) and THC (on average at
least two exposures per week in the last year), aged 18-27.
Detailed demographic data have been published elsewhere
(Dumont et al. 2010c).
Participants for both studies were recruited through adver-
tisements on the Internet and at local drug testing services.
Exclusion criteria for both studies included pregnancy and
(history of) psychiatric illness (assessed using the Structured
Clinical Interview for DSM-IV Axis I disorders, non-
patient version; First et al. 1994). Axis II disorders were
excluded using the Temperament and Character Inventory
(Svrakic et al. 1993), use of over-the-counter medication
within 2 months prior to the study start, (history of)
treatment for addiction problems, excessive smoking (>10
cigarettes/day) and orthostatic hypotension. Physical and
mental health was determined by assessment of medical
history, a physical and ECG examination as well as by
standard haematological and chemical blood examina-
tions, all conducted by a medical practitioner.
The time between the two studies exceeded 6 months.
Four volunteers participated in both studies. These volun-
teers were included in the studies according to the protocol
and all study procedures were trained before each study
started. The studies have been approved by the local
Medical Ethics Committee and performed in accordance
with the ethical standards laid down in the 1964 Declaration
of Helsinki. All participants gave their written informed
consent before participating in the study and were paid for
their participation.
Adverse events/missing data
Study 1 One participant had a mild adverse reaction
(local vascular reaction) during the ethanol infusion,
which led to premature interruption of the procedure, and
one other participant did not refrain from drug use; both
(one man, one woman) were excluded from further
participation and results obtained were not included in
t h ed a t aa n a l y s i s .
Study 2 One participant did not refrain from drug use, after
which further study participation was denied. Two partic-
ipants experienced an adverse event that was judged to be
likely related to study drug administration (one participant
developed a short-lasting (55 s) heart rate increase of
>180 bpm and another participant had mild hallucinations,
the latter subsiding along with other drug effects). These
participants were excluded from further participation; data
of completed study days obtained prior to these adverse
events were analysed as described.
Study procedure
Table 1 presents the time schedules of the events on a test
day for each study that are relevant for the present paper.
For a detailed description of a test day, see Dumont et al.
(2008, 2010c). In both studies, participants arrived in the
morning and were offered a light breakfast after a negative
urine drug screen (opiates, cocaine, benzodiazepines,
amphetamines, methamphetamines and delta-9-
tetrahydrocannabinol) as well as a negative alcohol breath
test and recording of signs and symptoms of possible health
problems. EEG data were acquired at 1000 hours, 30 min
prior to the first drug administration. Drug administration
(MDMA or placebo capsule in study 1; MDMA or placebo
capsule and THC or placebo inhalation in study 2) was
scheduled at 1030 hours. The ethanol or placebo infusion in
study 1 was started at 1100 hours for a duration of 3 h. The
second THC or placebo inhalation in study 2 was
administered at 1200 hours. In both studies, post-
assessment of EEG was conducted at 1230 hours, at
t h et i m ea r o u n dt h ep e a kc o n c e n t r a t i o no fM D M A( 2h ) .
Since subjective and cognitive effects of THC have been
shown within 15–60 min after administration, the second
THC inhalation was administered 30 min prior to the
EEG data acquisition. Volunteers were offered lunch at
1400 hours and were sent home at 1700 hours after a
medical check.
In addition to the EEG data, subjective, neuropsycho-
logical and physiological data were acquired, which have
Time Study 1: MDMA × ethanol Study 2: MDMA × THC
0845 Light breakfast Light breakfast
1000 EEG recordings EEG recordings
1030 Intake of MDMA or placebo capsule Intake of MDMA or placebo capsule and
1st THC or placebo inhalation
1100 Start ethanol or placebo infusion
1200 2nd THC or placebo inhalation
1230 EEG recordings EEG recordings
1400 Lunch/stop ethanol or placebo infusion Lunch
Table 1 Time schedule of
each day in the MDMA ×
ethanol and MDMA ×
THC study
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Drugs and dosages
3,4-Methylenedioxymethamphetamine
MDMA (or matched placebo) was given orally as a capsule
in a single dose of 100 mg. MDMA was obtained from
Lipomed AG, Arlesheim, Switzerland, and encapsulated
according to Good Manufacturing Practice (GMP) by the
Department of Clinical Pharmacy of the Radboud Univer-
sity Nijmegen Medical Centre. MDMA (100 mg) orally is a
relevant dose in the range of normal single recreational
dosages. Previous experiments in humans used doses up to
150 mg without serious adverse events.
Ethanol clamping
To standardize alcohol kinetics and dynamics, an intrave-
nous clamping procedure has been developed, which
minimizes variations in BAC that are high after oral
administration (Zoethout et al. 2008). Ethanol (or glucose
5% as its placebo) was administered continuously by
intravenous infusion of 10% ethanol in 5% glucose
solution, aimed to maintain an ethanol blood concentration
of 0.6‰ (0.6 g/L) for 3 h. The alcohol clamp was targeted
at 0.6‰, by which we aimed to provide the equivalent of
approximately two to three alcoholic beverages. This
concentration is just above the legal limit for traffic
participation in many Western countries and commonly
used in social settings as it is considered to be a safe and
relatively moderate level despite significant CNS effects
(Zoethout et al. 2009). The infusion rate was calculated
using frequent breath alcohol concentration measurements,
according to a previously designed algorithm (Zoethout et
al. 2008). Breath alcohol concentration was assessed using
a HONAC AlcoSensor IV® Intoximeter. The process was
semi-automated using a computer spreadsheet programme
w h i c hu s e sc h a n g e si nt h em e a s u r e db r e a t ha l c o h o l
concentrations to calculate the infusion rate that is needed
to maintain the ethanol level at 0.6‰. The operator of the
breath alcoholmeter and the ethanol infusion pump was
unblinded for alcohol treatment, but did not communicate
with the study team or the participant about the results at
any stage during the trial and was not involved in the
analyses. A sham procedure including a mock spreadsheet
was used on ethanol–placebo occasions.
delta-9-Tetrahydrocannabinol
THC kinetics are highly variable in a free smoking
procedure. To minimize variation due to inhalation volume
and duration as well as THC content, a standardized
procedure using a vaporizer, which has been shown to
produce reliable and reproducible THC levels (Strougo et
al. 2008), was used to administrate THC.
THC was purified according to GMP-compliant proce-
dures (Farmalyse BV, Zaandam, the Netherlands) from the
flowers of Cannabis sativa grown under Good Agricultural
Practice (Bedrocan BV Medicinal Cannabis, Veendam, the
Netherlands; Choi et al. 2004; Hazekamp et al. 2004). Each
dose (4, 6 and 6 mg) of THC (>98% purity by HPLC/
GC) was dissolved in 200 μL 100 vol.% ethanol. THC
w a ss t o r e di nt h ed a r ka t−20°C in 1-mL amber glass
vials containing a Teflon screw-cap secured with
Parafilm to minimize evaporation. The solvent was used
as placebo.
On each study day, THC (4, 6 and 6 mg) or placebo was
administered at 90-min intervals by inhalation using a
Volcano® vaporizer (Storz-Bickel GmbH, Tüttlingen,
Germany), a validated method of intrapulmonary THC
administration (Abrams et al. 2007; Hazekamp et al. 2006;
Zuurman et al. 2008). The same regimen was also used
with MDMA administration where 4 mg THC was
administered together with MDMA and the two subsequent
dosesof6mgofTHCwereadministered90and180minafter
MDMA administration. Within 5 min before administration,
THC was vaporized at a temperature of about 225°C and the
vapour was stored in a polythene bag equipped with a valved
mouthpiece, preventing the loss of THC between inhalations.
The transparant bag was covered with a black plastic bag to
prevent unblinding. The personnel responsible for drug
preparation was not involved in any other part of the study.
Participants were not allowed to speak, were instructed to
inhale deeply and hold their breath for 10 s after each
inhalation. Within 2–3 min, the bag was to be fully emptied.
The inhalation procedure was practiced at screening
using the solvent only. The inhalation schedule was
predicted to cause THC plasma concentrations and
effects corresponding to the THC contents in roughly
one marijuana cigarette. The decision to proceed to the
next higher THC dose was made by a physician based on
adverse events and physical signs.
Electrophysiological recordings
The EEG data were recorded using an elastic cap with 27
tin electrodes according to the 10–20 electrode international
system. Data were referenced to the left mastoid with the
ground electrode placed at the right mastoid. Vertical
electrooculogram was recorded from electrodes attached
above and below the left eye and the horizontal electrooc-
ulogram from the outer canthi of both eyes. Electrode
impedance was below 5 kΩ at the start of the recording
session. EEG and EOG were amplified with a bandwidth of
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were asked to sit quietly for 3 min with eyes closed, during
which resting-state EEG was recorded.
Electrophysiological analysis
EEG and EOG data were analyzed using the Brain
Vision Analyzer software (www.brainproducts.com).
EEG signals were re-referenced off-line to the average of
all EEG electrodes, and the sampling rate was changed to
256 Hz with a high-pass filter of 0.04 Hz, low-pass filter
of 40 Hz and a notch filter of 50 Hz. The 3-min
continuous EEG data were segmented into 2-s epochs.
First, a full segment baseline correction was applied.
Subsequently, trials with artefacts were rejected from
further analysis (absolute amplitude criterion of 120 μV
and low activity criterion of 0.5 μV within a 100-ms time
window for EEG data). Then, ocular artefact correction
was conducted according to the Gratton et al. (1983)
algorithm. Finally, EEG data were Fourier-transformed
(Hanning window length of 20%) and subsequently ln-
transformed. Based on previous literature (e.g. Böcker et
al. 2010;I l a ne ta l .2004, 2005), we selected frontal (Fz,
F3, F4), central (Cz, C3, C4) and parietal (Pz, P3, P4)
electrodes for the analysis.
Since alpha oscillations show large interindividual
differences (Klimesch 1999) and previous drug studies
reported not only a change in absolute power of specific
frequency bands but also in the peak frequency of alpha
oscillations (Ehlers et al. 1989), the analysis of fixed
frequency bands has major limitations. Klimesch (1999)
suggested adjusting the frequency windows of alpha and
theta for each individual by using individual alpha peak
frequency (IAF) as an anchor point. More specifically,
individual frequency bandwidths for alpha and theta bands
are determined as a percentage of IAF (Doppelmayr et al.
1998). Moreover, Klimesch (1999) suggested dividing
alpha oscillations into three frequency bands: lower-1 alpha
(i.e. 0.6*IAF–0.8*IAF), lower-2 alpha (0.8*IAF–1*IAF)
and upper alpha (i.e. IAF–1.2*IAF). Similar to Klimesch
(1999), in the present study, the power of individual-
defined frequency bands was calculated. Individual fre-
quency bands were calculated based on the mean IAF of
each participant. First, for each participant, IAF was
defined as the frequency at which alpha power was
maximum within 7.5–15 Hz over the occipital electrodes
(O1, Oz, O2) in the eyes closed condition. Visual
inspection was conducted for peak frequencies occurring
at the boundaries of the search window. Subsequently,
power estimates were derived from the average for the theta
(0.4*IAF–0.6*IAF), lower-1 alpha (0.6*IAF–0.8*IAF),
lower-2 alpha (0.8*IAF–1*IAF) and upper alpha (1*IAF–
1.2*IAF) bands (Doppelmayr et al. 1998).
Statistical analysis
Since several participants did not complete the whole
experiment as described in detail above, multivariate
analysis of variance with repeated measures MANOVA
would limit the sample size. Therefore, mixed model
analyses of variance (SPSS 16.0) were conducted to
examine the effects of drug administration alone and in
combination on logarithmically transformed EEG data,
separately for each study (study 1: MDMA in combination
with ethanol; study 2: MDMA in combination with THC).
First, separately for each drug condition, IAF and theta,
lower-1 alpha, lower-2 alpha and upper alpha power before
drug administration were subtracted from IAF and power in
the specific frequency band after drug administration,
respectively. The difference value of power was then
entered in the mixed model analysis of variance, separately
for IAF and theta, lower-1 alpha, lower-2 alpha and upper
alpha power. Participant was used as subject variable. Fixed
factors were MDMA (MDMA vs. placebo), THC or ethanol
(THC orethanol vs. placebo). For theta, lower-1 alpha, lower-
2 alpha and upper alpha power, the fixed factors—lead
[frontal (Fz, F3, F4) vs. central (Cz, C3, C4) vs. parietal (Pz,
P3, P4)] and laterality (left vs. right vs midline)—were added
to the model. Power values after each drug administration and
at each electrode site were treated as repeated measurements.
If the interaction between MDMA × THC (or ethanol) was
significant, post hoc analyses were conducted to investigate
the effects of MDMA alone, THC (or ethanol) alone and
combined MDMA+THC (or MDMA+ethanol) relative to
placebo. The alpha level of significance was set at 0.05 two-
tailed. Results are presented as mean ± SD unless indicated
otherwise.
Repeated measures ANOVA was used to examine the
pharmacokinetics of the drugs (see also Dumont et al.
2009a, 2010b).
Results
Pharmacokinetics
Study 1 Mean MDMA maximal plasma concentration was
202.5±74.1 μg/L 150 min after drug intake, and its kinetics
did not differ between single MDMA or combined MDMA
and ethanol administration (see Dumont et al. 2010b for
more details). Mean BAC during the pseudosteady state
phase was 0.56±0.06‰.
Study 2 Mean MDMA maximal plasma concentration was
213.3±29.6 μg/L at 105 min after drug administration and
showed minimal decline during the sampling period (on
average 168.3±20.2 μg/L at 300 min after drug adminis-
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alone and MDMA plus THC drug conditions (see Dumont et
al.2009a for more details). THC and 11-OH-THC (one of its
two most important metabolites) consistently showed peak
concentrations 5 min after administration and declined
thereafter, whereas 11-nor-9-carboxy-THC (the other impor-
tant metabolite of THC) concentrations rose throughout the
sampling period. Plasma THC and metabolite concentrations
did not differ significantly between the THC-alone and
MDMA+THC conditions (Dumont et al. 2009a).
Individual alpha peak frequency
Study 1 (MDMA–ethanol interaction)
All participants presented a clear peak in the alpha
frequency band in all conditions, except for the ethanol
alone condition of one participant and in three drug
conditions (placebo, ethanol alone and MDMA+ethanol
condition) of a second participant. For these data points,
IAF and individual frequency bands could not be calculated.
Therefore, these data points were excluded from the mixed
model analyses of variance.
Table 2 presents mean IAF prior to and after drug
administration, separately for the four conditions. IAF
decreased significantly after ethanol administration and
increased significantly after MDMA intake compared to
placebo intake [F(1,34.0)=12.51, p=0.001 and F(1,33.4)=
19.17, p<0.001, respectively]. No significant interaction
effect was found between MDMA and ethanol.
Study 2 (MDMA–THC interaction)
All participants presented a clear peak in the alpha frequency
band in all conditions, except for three participants in the
placebo condition, two participants in the THC alone
condition, two participants in the combined MDMA and
THC condition, and one participant in the MDMA alone
condition. These data points were excluded from the mixed
model analysis of variance.
Table 3 presents mean IAF prior to and after drug
administration, separately for the four conditions. As
expected from study 1, MDMA significantly increased
IAF as compared to placebo [F(1,37.8)=15.15, p<0.001]. No
significant main effect of THC administration or a
significant interaction effect of THC and MDMA was
found.
Individual frequency bands
Since mean IAF was affected by the administration of
ethanol and MDMA, the analysis of individual frequency
bands is more valid than the analyses of fixed frequency
bands. Based on the IAFs, mean power for theta, lower-1
alpha, lower-2 alpha and upper alpha were calculated (see
“Methods” section).
Tables 2 and 3 present mean power of theta, lower-1
alpha, lower-2 alpha and upper alpha oscillations before
and after drug administration for the four conditions from
study 1 and study 2, respectively. The mean width of each
individual frequency bands is also reported. Note that the
frequency bands of theta and lower-1 alpha coincide with
the traditional fixed theta frequency band (4–8 Hz).
Study 1
The results of the mixed model analysis for mean
‘individualized’ theta power (mean range, 4.4–6.4 Hz)
revealed a significant reduction of theta power after
MDMA and an increased theta power after ethanol
administration compared to placebo [F(1,49.2)=107.36, p<
0.001; F(1,38.8)=22.63, p<0.001], without an interaction
effect of MDMA and ethanol. Furthermore, a significant
ethanol × lead interaction effect [F(2,96.0)=3.90, p=0.023]
and MDMA × lead effect [F(2,100.4)=3.55, p=0.032]
Table 2 Mean individualized alpha peak frequency and mean power of theta, lower-1 alpha, lower-2 alpha and upper-alpha oscillations (across
frontal, central and parietal sites) before and after drug administration for study 1 (MDMA × ethanol)
Placebo MDMA Ethanol MDMA+ethanol
Pre Post Pre Post Pre Post Pre Post
IAF 10.5 (0.9) 10.5 (0.9) 10.4 (1.0) 10.9 (1.1) 10.5 (0.7) 10.1 (0.8) 10.4 (0.9) 10.5 (0.9)
Theta (4.4–6.4 Hz) 0.24 (0.13) 0.27 (0.12) 0.23 (0.11) 0.19 (0.07) 0.21 (0.09) 0.28 (0.16) 0.23 (0.11) 0.21 (0.09)
Lower-1 alpha (6.4–8.4 Hz) 0.27 (0.19) 0.30 (0.18) 0.28 (0.18) 0.21 (0.10) 0.25 (0.17) 0.37 (0.26) 0.27 (0.19) 0.27 (0.15)
Lower-2 alpha (8.4–10.4 Hz) 0.40 (0.21) 0.42 (0.21) 0.48 (0.25) 0.42 (0.19) 0.42 (0.20) 0.56 (0.24) 0.41 (0.26) 0.45 (0.26)
Upper alpha 10.4–12.4 Hz) 0.50 (0.28) 0.53 (0.28) 0.52 (0.24) 0.51 (0.25) 0.48 (0.19) 0.58 (0.24) 0.44 (0.23) 0.49 (0.27)
Standard deviations are given in parentheses
IAF individualized alpha peak frequency
Psychopharmacology (2011) 213:745–756 751revealed the greatest effect of ethanol and MDMA over
parietal sites. No significant interaction effects were found
with the factor laterality.
Regarding alpha power, analyses with individualized
lower-1 alpha (mean range, 6.4–8.4 Hz), lower-2 alpha (8.4–
10.4 Hz) and upper alpha (10.4–12.4 Hz) confirmed previous
findings of significantly enhanced alpha power after ethanol
administration compared to placebo [F(1,118.2)=72.87, p<
0.001, F(1,85.6)=86.21, p<0.001, F(1,378.3)=34.13, p<0.001
for lower-1 alpha, lower-2 alpha, and upper alpha, respec-
tively] and significantly attenuated alpha power after
MDMA intake compared to the placebo condition
[F(1,190.8)=152.27, p<0.001, F(1,77.3)=44.76, p<0.001,
F(1,206.6)=10.55, p=0.001 for lower-1 alpha, lower-2 alpha,
and upper alpha, respectively]. MDMA did not signifi-
cantly interact with ethanol. A significant ethanol × lead
interaction effect for lower-1 alpha power [F(2,141.5)=
3.29, p=0.040] revealed the greatest enhancement of
lower-1 alpha power after ethanol over parietal sites. No
significant interaction effects were found with the factor
laterality.
Study 2
Mixed model analyses for mean individualized theta power
(mean range, 4.4–6.4 Hz) and mean individualized lower-1
alpha power (mean range, 6.4–8.4 Hz) revealed similar
results: Whereas EEG power increased after placebo, EEG
power decreased after the administration of MDMA alone,
THC alone, and combined MDMA and THC [significant
main effects ofMDMA (F(1,107.8)=23.18,p<0.001;F(1,54.1)=
53.6, p<0.001 for theta and lower-1 alpha power, respec-
tively) and THC (F(1,90.3)=7.8,p=0.006;F(1,31.3)=13.07,p=
0.001 for theta and lower-1 alpha power, respectively)].
Additionally, as shown in Figs. 1 and 2,s i g n i f i c a n tT H C×
MDMA interaction effects [F(1,110.6)=17.2, p<0.001;
F(1,37.3)=17.8, p<0.001 for theta and lower-1 alpha power,
respectively] indicated that the combined effect produced by
the administration of MDMA and THC on theta and lower-1
alpha power is not equal to the sum of their separate
effects. As illustrated in Figs. 1 and 2, the attenuation of
power when drugs were taken in combination appears to
be considerably less than the sum of the drugs alone. Post
hoc analyses to compare placebo with drug alone and
combined drug intake revealed significant MDMA-alone
effects [F(1,11.4)=20.97, p=0.001; F(1,11.1)=16.7, p=0.002
for theta and lower-1 alpha power, respectively] and
combined MDMA-THC effects [F(1,11.9)=10.46, p=
0.007; F(1,12.4)=10.61, p=0.007 for theta and lower-1
alpha power, respectively] and trends for THC-alone drug
effect [F(1,15.2)=4.84, p=0.044; F(1,13.2)=3.60, p=0.080
for theta and lower-1 alpha power, respectively]. No
significant interaction effects were found with the factors
laterality or lead.
Mixed model analysis for lower-2 alpha power (mean
range, 8.4–10.4 Hz) yielded a main effect of MDMA
[F(1,77.1)=24.2, p<0.001], interaction effect of THC ×
MDMA [F(1,62.8)=6.3, p=0.015] and a significant interac-
tion effect of THC × MDMA × lead [F(1,85.0)=3.2, p=
0.047]. Post hoc tests per lead to compare placebo with
drug alone and combined drug intake revealed that at
frontal leads, the intake of MDMA or THC alone did not
significantly affect lower-2 alpha power, whereas the
combination of MDMA and THC significantly decreased
lower-2-alpha power [F(1,10.0)=10.28, p=0.009]. As illus-
Table 3 Mean individualized alpha peak frequency and mean power of theta, lower-1 alpha, lower-2 alpha and upper-alpha oscillations (across
frontal, central and parietal sites) before and after drug administration for study 2 (MDMA × THC)
Placebo MDMA THC MDMA+THC
Pre Post Pre Post Pre Post Pre Post
IAF 10.8 (1.4) 10.7 (1.2) 10.3 (1.0) 10.8 (1.2) 10.0 (1.2) 9.9 (1.0) 10.2 (0.9) 10.6 (1.0)
Theta (4.4–6.4 Hz) 0.19 (0.07) 0.23 (0.09) 0.21 (0.10) 0.17 (0.07) 0.20 (0.13) 0.17 (0.07) 0.21 (0.06) 0.17 (0.07)
Lower-1 alpha (6.4–8.4 Hz) 0.19 (0.10) 0.23 (0.11) 0.22 (0.12) 0.17 (0.10) 0.20 (0.12) 0.18 (0.08) 0.21 (0.08) 0.16 (0.08)
Lower-2 alpha (8.4–10.4 Hz) 0.32 (0.23) 0.29 (0.22) 0.35 (0.23) 0.30 (0.28) 0.32 (0.23) 0.32 (0.22) 0.34 (0.19) 0.25 (0.17)
Upper alpha (10.4–12.4 Hz) 0.32 (0.24) 0.29 (0.25) 0.31 (0.19) 0.26 (0.22) 0.31 (0.20) 0.33 (0.22) 0.32 (0.17) 0.26 (0.20)
Standard deviations are given in parentheses
IAF individualized alpha peak frequency
Fig. 1 Individualized theta power before (pre) and after (post) the
administration of MDMA alone, THC alone, combined MDMA and
THC, and placebo. Error bars represent the standard error of the mean
752 Psychopharmacology (2011) 213:745–756trated in Fig. 3, this pattern of drug effects was also
present at parietal sites [F(1,10.8)=5.41, p=0.040]. No
significant interaction effects were found with the factor
laterality.
Mixed model analysis for upper alpha power (mean
range: 10.4–12.4 Hz) revealed a significant main effect of
MDMA [F(1,185.3)=27.9, p<0.001] and a MDMA × THC
interaction effect [F(1,68.6)=6.09, p=0.016]. Post hoc
comparisons of each drug condition with the placebo
condition did not yield any significant results, probably
due to the large inter-individual variability (see standard
deviations in Table 3). No significant interaction effects
were found with the factors laterality or lead.
Discussion
The aim of the present report was to examine the effects of
MDMA alone and in combination with (1) THC or (2)
ethanol on ongoing EEG oscillations in healthy volunteers.
Consistent with previous findings (Ehlers et al. 1989),
mean individual alpha peak frequency decreased after alcohol
administration. In contrast, administration of MDMA in-
creased individual alpha peak frequency. These findings
indicate that it is very important to use individualized
frequency bands to calculate EEG power (Klimesch 1999)
instead of broad fixed frequency bands, which the majority
of previous studies have used.
As expected from previous literature (Böcker et al. 2010;
Frei et al. 2001; Little 1999), theta oscillations and lower-1
alpha oscillations, which overlap the traditional theta
frequency band, were attenuated after the administration
of MDMA alone and THC alone and increased after the
intake of ethanol alone compared to placebo. Alpha
oscillations were decreased after MDMA alone intake and
increased after the administration of ethanol alone, also
replicating previous findings (Frei et al. 2001; Little 1999).
Consistent with the majority of previous studies (Böcker et
al. 2010; Ilan et al. 2004, 2005; Zuurman et al. 2008, 2010),
no significant changes for alpha power after THC administra-
tionwerefound.Note thatincreases inalpha powerafterTHC
intake have been reported, especially during THC-induced
feelings of euphoria (Lukas et al. 1995), leading to the
hypothesis that fluctuations in alpha power after THC
administration coincide with fluctuations in feelings of
euphoria (Lukas et al. 1995). Since EEG data and feelings
of euphoria were not continuously recorded in the present
study, this hypothesis could not be tested.
This is the first study that investigated the effects of the
co-administration of THC or ethanol with MDMA on
ongoing EEG oscillations. Ethanol and MDMA did not
interact with regard to their effects on EEG power, i.e. the
effects of combined intake was similar to the sum of the
single drug effects. Regarding the co-administration of
THC and MDMA, combined intake of MDMA and THC
affected theta and lower-1 alpha power less than the sum of
the single drug effects, but exacerbated the reductions in
lower-2 alpha power. Although no corrections were made
for multiple comparisons, drug effects appeared to be
relatively large and main drug effects were consistent with
previous literature.
What could be the functional interpretation of the present
findings? Based on the suggestion that EEG oscillations are
Fig. 3 Individualized lower-2 alpha power before (pre) and after
(post) the administration of MDMA alone, THC alone, combined
MDMA and THC, and placebo at frontal, central, and parietal sites.
Error bars represent the standard error of the mean
Fig. 2 Individualized lower-1 alpha power before (pre) and after
(post) the administration of MDMA alone, THC alone, combined
MDMA and THC, and placebo. Error bars represent the standard
error of the mean
Psychopharmacology (2011) 213:745–756 753related to alertness (Oken et al. 2006), MDMA, THC and
alcohol may generally affect alertness and consequently
change theta and alpha power. However, single drug effects
on alertness (i.e. decreased feelings of alertness by THC
and alcohol, but not by MDMA; Dumont et al. 2008,
2010c) do not match the drug effects on EEG oscillations
(i.e. decreased power by MDMA and THC and increased
power by ethanol).
Recent animal and human studies investigating task-
induced EEG oscillations indicate that EEG oscillations are
related to specific cognitive processes rather than general
alertness. More specifically, it has been suggested that task-
induced increases in theta power and the phase relationship
between theta and gamma oscillations are important for
memory processes (Duzel et al. 2010;K a h a n a2006;
Klimesch 1999; Knyazev 2007). Recently, it has also been
argued that theta oscillations reflect a “more general brain
integrative mechanism” rather than an integrative mecha-
nism specific for memory processes (Sauseng et al. 2010).
Task-induced alpha oscillations have been related to top-
down inhibitory control processes of visual information
(Jensen et al. 2002; Knyazev 2007; Sauseng et al. 2009),
necessary for optimal task performance. Ongoing back-
ground EEG oscillations may also be closely related to
specific cognitive processes. For example, a significant
association between decreased theta power at rest and
impaired working memory performance after cannabis use
has been reported (Böcker et al. 2010). The present finding
that co-administration of MDMA with either THC or
alcohol did not exacerbate single drug-induced effects on
theta and lower-1 alpha power corresponds to the previous
findings of Dumont et al. (2008, 2010c) that the co-
administration of MDMA with either THC or alcohol did
not exacerbate single drug-induced impairments in memory
and psychomotor performance. In contrast, the co-
administration of MDMA with THC did exacerbate the
reductions in lower-2 alpha power, which may be viewed as
a contrasting finding at first glance. However, lower-2
alpha power has been specifically related to general
attentional processes, whereas upper alpha power seems to
be associated with semantic memory processes (Klimesch
1999). Therefore, the co-administration of MDMA with
THC may not exacerbate the impairment in memory and
psychomotor performance, but it may enhance attentional
impairment.
How could changes in ongoing EEG oscillations be
associated with cognitive impaired performance? It has
been speculated that decreased theta power at rest after
cannabis administration reflects desynchronization of on-
going theta oscillations, which interferes with phase
resetting of theta that is needed for optimal memory
performance (Böcker et al. 2010). Following this reasoning,
one may predict that the increased theta power after alcohol
intake leads to improved working memory performance.
However, impaired memory has been reported after alcohol
intake (Dumont et al. 2008). It may be speculated that the
phase reset of oscillations and the phase relationship
between different oscillations (i.e. cross-spectrum frequency
coupling) are important for human information processing
rather than the general increase/decrease in power. Subse-
quently, it could be speculated that both an increase and
decrease of ongoing theta oscillations during a resting
condition interfere with phase resetting of theta oscillations,
necessary for correct behavioural performance. Therefore,
decreased as well as increased ongoing theta oscillations may
lead to incorrect phase reset of theta oscillations after a task-
relevant stimulus, resulting in reduced task-induced theta and
impaired performance. Correspondingly, it has recently been
demonstratedthatethanolreducesthenormallyobservedtask-
induced theta oscillations in healthy volunteers (Boha et al.
2009). The same mechanism may apply to alpha oscillations.
Ongoing alpha oscillations in the present study were
decreased after administration of MDMA alone and com-
bined administration of THC and MDMA, but increased
after ethanol intake. It may be speculated that decreased and
increased ongoing alpha oscillations lead to incorrect phase
reset of alpha oscillations during task performance, resulting
in reduced task-induced alpha oscillations and impaired
performance. Future studies should test this hypothesis and
investigatehowdecreasedaswellasincreasedsynchronization
of ongoing EEG oscillations might hamper phase resetting.
Since MDMA, ethanol and THC influence multiple
neurotransmitter systems (e.g. (Vengeliene et al. 2008), it is
difficult to elucidate the mechanisms underlying the drug
effects on ongoing EEG oscillations. The effects of ethanol
have been suggested to be mediated by increasing the
action of the inhibitory neurotransmitter GABA (Mitchell et
al. 2008), whereas the modulation of EEG after MDMA is
suggested to be predominantly mediated by the 5-HT and
NA system (Frei et al. 2001). The literature offers no clear
explanation on whether or how cannabinoids affect EEG
oscillations. Therefore, it is difficult to predict how the EEG
would be affected by interactions of these neurotransmitter
changes following different drug combinations. The results
may suggest that the cannabinoid system has additive
effects on the GABAergic system, where CB1 receptors are
located on GABAergic neurons, but is infra-additive with
respect to the blockade of presynaptic transporters, which
might by and in itself create maximal reverse CB1
transmission, preventing additive effects of THC.
In conclusion, administration of MDMA, THC and
ethanol change ongoing EEG oscillations, as reflected, in
this study, in changes in theta and alpha power. Moreover,
combined intake of MDMA and THC, but not of MDMA
and alcohol, affects ongoing EEG oscillations differently
than the sum of either one drug alone. Future studies may
754 Psychopharmacology (2011) 213:745–756examine whether these changes are related to the impaired
cognitive performance that has previously been found after
acute drug administration.
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